Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review

Detalhes bibliográficos
Autor(a) principal: Fantin,João Paulo Pretti
Data de Publicação: 2021
Outros Autores: Furst,Maria Claudia Bicudo, Tobias-Machado,Marcos, Muller,Roberto Lodeiro, Machado,Roberto Dias, Santos,Alexandre Cesar, Magnabosco,Wesley Justino, Alcantara-Quispe,Cinthia, Faria,Eliney Ferreira
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000300484
Resumo: ABSTRACT Prostate cancer is the most common invasive cancer in men. Radical prostatectomy (RP) is a definitive treatment option, but biochemical recurrence can reach 40%. Salvage lymphadenectomy is a relatively recent approach to oligometasis and has been rapidly diffused primarily due to improvement in imaging diagnosis and results showing possibly promising therapy. A systematic literature review was performed in March 2020, according to the PRISMA statement. We excluded studies with patients with suspicion or confirmation of visceral and / or bone metastases. A total of 27 articles were included in the study. All studies evaluated were single arm, and there were no randomized studies in the literature. A total of 1,714 patients received salvage lymphadenectomy after previous treatment for localized prostate cancer. RP was the most used initial therapeutic approach, and relapses were based on PET / CT diagnosis, with Coline-11C being the most widely used radiopharmaceutical. Biochemical response rates ranged from 0% to 80%. The 5 years - Free Survival Biochemical recurrence was analyzed in 16 studies with rates of 0% up to 56.1%. The articles do not present high levels of evidence to draw strong conclusions. However, even if significant rates of biochemical recurrence are not evident in all studies, therapy directed to lymph node metastases may present good oncological results and postpone the onset of systemic therapy. The long-term impact in overall survival and quality of life, as well as the best strategies for case selection remains to be determined.
id SBU-1_1dafbfa5e0fbea6e4197dc64134cf73a
oai_identifier_str oai:scielo:S1677-55382021000300484
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic reviewProstate cance, familial [Supplementary Concept]Lymph NodesSystematic Reviews as TopicABSTRACT Prostate cancer is the most common invasive cancer in men. Radical prostatectomy (RP) is a definitive treatment option, but biochemical recurrence can reach 40%. Salvage lymphadenectomy is a relatively recent approach to oligometasis and has been rapidly diffused primarily due to improvement in imaging diagnosis and results showing possibly promising therapy. A systematic literature review was performed in March 2020, according to the PRISMA statement. We excluded studies with patients with suspicion or confirmation of visceral and / or bone metastases. A total of 27 articles were included in the study. All studies evaluated were single arm, and there were no randomized studies in the literature. A total of 1,714 patients received salvage lymphadenectomy after previous treatment for localized prostate cancer. RP was the most used initial therapeutic approach, and relapses were based on PET / CT diagnosis, with Coline-11C being the most widely used radiopharmaceutical. Biochemical response rates ranged from 0% to 80%. The 5 years - Free Survival Biochemical recurrence was analyzed in 16 studies with rates of 0% up to 56.1%. The articles do not present high levels of evidence to draw strong conclusions. However, even if significant rates of biochemical recurrence are not evident in all studies, therapy directed to lymph node metastases may present good oncological results and postpone the onset of systemic therapy. The long-term impact in overall survival and quality of life, as well as the best strategies for case selection remains to be determined.Sociedade Brasileira de Urologia2021-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000300484International braz j urol v.47 n.3 2021reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/s1677-5538.ibju.2020.0051info:eu-repo/semantics/openAccessFantin,João Paulo PrettiFurst,Maria Claudia BicudoTobias-Machado,MarcosMuller,Roberto LodeiroMachado,Roberto DiasSantos,Alexandre CesarMagnabosco,Wesley JustinoAlcantara-Quispe,CinthiaFaria,Eliney Ferreiraeng2021-03-24T00:00:00Zoai:scielo:S1677-55382021000300484Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2021-03-24T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review
title Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review
spellingShingle Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review
Fantin,João Paulo Pretti
Prostate cance, familial [Supplementary Concept]
Lymph Nodes
Systematic Reviews as Topic
title_short Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review
title_full Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review
title_fullStr Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review
title_full_unstemmed Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review
title_sort Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review
author Fantin,João Paulo Pretti
author_facet Fantin,João Paulo Pretti
Furst,Maria Claudia Bicudo
Tobias-Machado,Marcos
Muller,Roberto Lodeiro
Machado,Roberto Dias
Santos,Alexandre Cesar
Magnabosco,Wesley Justino
Alcantara-Quispe,Cinthia
Faria,Eliney Ferreira
author_role author
author2 Furst,Maria Claudia Bicudo
Tobias-Machado,Marcos
Muller,Roberto Lodeiro
Machado,Roberto Dias
Santos,Alexandre Cesar
Magnabosco,Wesley Justino
Alcantara-Quispe,Cinthia
Faria,Eliney Ferreira
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Fantin,João Paulo Pretti
Furst,Maria Claudia Bicudo
Tobias-Machado,Marcos
Muller,Roberto Lodeiro
Machado,Roberto Dias
Santos,Alexandre Cesar
Magnabosco,Wesley Justino
Alcantara-Quispe,Cinthia
Faria,Eliney Ferreira
dc.subject.por.fl_str_mv Prostate cance, familial [Supplementary Concept]
Lymph Nodes
Systematic Reviews as Topic
topic Prostate cance, familial [Supplementary Concept]
Lymph Nodes
Systematic Reviews as Topic
description ABSTRACT Prostate cancer is the most common invasive cancer in men. Radical prostatectomy (RP) is a definitive treatment option, but biochemical recurrence can reach 40%. Salvage lymphadenectomy is a relatively recent approach to oligometasis and has been rapidly diffused primarily due to improvement in imaging diagnosis and results showing possibly promising therapy. A systematic literature review was performed in March 2020, according to the PRISMA statement. We excluded studies with patients with suspicion or confirmation of visceral and / or bone metastases. A total of 27 articles were included in the study. All studies evaluated were single arm, and there were no randomized studies in the literature. A total of 1,714 patients received salvage lymphadenectomy after previous treatment for localized prostate cancer. RP was the most used initial therapeutic approach, and relapses were based on PET / CT diagnosis, with Coline-11C being the most widely used radiopharmaceutical. Biochemical response rates ranged from 0% to 80%. The 5 years - Free Survival Biochemical recurrence was analyzed in 16 studies with rates of 0% up to 56.1%. The articles do not present high levels of evidence to draw strong conclusions. However, even if significant rates of biochemical recurrence are not evident in all studies, therapy directed to lymph node metastases may present good oncological results and postpone the onset of systemic therapy. The long-term impact in overall survival and quality of life, as well as the best strategies for case selection remains to be determined.
publishDate 2021
dc.date.none.fl_str_mv 2021-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000300484
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000300484
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/s1677-5538.ibju.2020.0051
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.47 n.3 2021
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318078052270080